Loading...
Checkpoint Therapeutics Q4 2020 Earnings Report
Announced financial results for the full-year ended December 31, 2020 and recent corporate highlights.
Key Takeaways
Checkpoint Therapeutics announced its full-year 2020 financial results, highlighting the progress of cosibelimab in metastatic cutaneous squamous cell carcinoma (mCSCC) and positive interim data from its Phase 1 program. The company's registration-enabling study in mCSCC is approximately 90% enrolled, with full enrollment anticipated shortly, and top-line results expected in the second half of 2021.
Cosibelimab registration path in mCSCC is solidifying.
Positive interim data from pivotal Phase 1 program was announced.
Registration-enabling study in mCSCC is approximately 90% enrolled, with full enrollment anticipated shortly.
Full top-line results are expected in the second half of 2021.
Forward Guidance
Checkpoint Therapeutics anticipates a transformative year, focusing on progress towards its first BLA submission with the FDA for cosibelimab in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...